{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:37:24Z","timestamp":1775684244825,"version":"3.50.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Type I interferons (IFN) are immune-stimulatory cytokines involved in antiviral and antitumor immune responses. They enhance the efficacy of immunogenic anticancer therapies such as radiotherapy by activating both innate and adaptive immune cells. Macrophages are one of the most abundant innate immune cells in the immune microenvironment of melanoma brain metastases (MBM) and can exert potent immune-suppressive functions. Here, we investigate the potential of tumoral type I IFNs to repolarize tumor-associated macrophages (TAM) in two murine MBM models and assess the effects of radiotherapy-induced type I IFN on TAMs in a transcriptomic MBM patient dataset. In mice, we describe a proinflammatory M1-like TAM phenotype induced by tumoral IFN\u03b2 and identify a myeloid type I IFN-response signature associated with a high M1\/M2-like TAM ratio. Following irradiation, patients with MBM displaying a myeloid type I IFN-response signature showed increased overall survival, providing evidence that tumoral IFN\u03b2 supports an effective antitumor immune response by re-educating immune-regulatory TAM. These findings uncover type I IFN\u2013inducing therapies as a potential macrophage-targeting therapeutic approach and provide a rationale for combining radiotherapy with concomitant immunotherapy to improve treatment response in patients with MBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our study shows that re-education of tumor-associated macrophages by tumoral IFN\u03b2 translates into improved clinical outcome in patients with melanoma brain metastases, providing pathomechanistic insights into synergistic type I interferon\u2013inducing therapies with immunotherapies and warranting investigation of IFN\u03b2 as a predictive biomarker for combined radioimmunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0024","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T05:11:04Z","timestamp":1721970664000},"page":"2189-2202","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4275-2115","authenticated-orcid":false,"given":"Julia","family":"Gellert","sequence":"first","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-2504","authenticated-orcid":false,"given":"Dennis A.","family":"Agardy","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."},{"name":"4Faculty of Bioscience, Heidelberg University, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-787X","authenticated-orcid":false,"given":"Swaminathan","family":"Kumar","sequence":"additional","affiliation":[{"name":"5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7894-9131","authenticated-orcid":false,"given":"Alexandros","family":"Kourtesakis","sequence":"additional","affiliation":[{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"4Faculty of Bioscience, Heidelberg University, Heidelberg, Germany."},{"name":"6German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neurooncology, Heidelberg, Germany."},{"name":"7Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8957-5319","authenticated-orcid":false,"given":"Tamara","family":"Boschert","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"8Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz)\u2014A Helmholtz Institute of the DKFZ, Mainz, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7064-4103","authenticated-orcid":false,"given":"Kristine","family":"J\u00e4hne","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-2390","authenticated-orcid":false,"given":"Michael O.","family":"Breckwoldt","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"9Department of Neuroradiology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-7574","authenticated-orcid":false,"given":"Lukas","family":"Bunse","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."},{"name":"10DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany."},{"name":"11Hertie Network of Excellence in Clinical Neuroscience, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"6German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neurooncology, Heidelberg, Germany."},{"name":"7Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"name":"5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."},{"name":"7Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany."},{"name":"8Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz)\u2014A Helmholtz Institute of the DKFZ, Mainz, Germany."},{"name":"10DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany."},{"name":"12Immune Monitoring Unit, National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-4269","authenticated-orcid":false,"given":"Theresa","family":"Bunse","sequence":"additional","affiliation":[{"name":"1German Cancer Research Center (DKFZ) Heidelberg, Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany."},{"name":"2German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Heidelberg, Germany."},{"name":"3Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2025032818102867900_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2025032818102867900_bib2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res"},{"key":"2025032818102867900_bib3","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"2025032818102867900_bib4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells","volume":"122","author":"Drobits","year":"2012","journal-title":"J Clin Invest"},{"key":"2025032818102867900_bib5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"2025032818102867900_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"2025032818102867900_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2025032818102867900_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2025032818102867900_bib9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"2025032818102867900_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-\u03b2 signaling axis mediated via the receptor IFNAR1","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat Immunol"},{"key":"2025032818102867900_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2025032818102867900_bib12","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"2025032818102867900_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front Oncol"},{"key":"2025032818102867900_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jaci.2023.04.022","article-title":"The regulatory landscape of macrophage interferon signaling in inflammation","volume":"152","author":"Siebeler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2025032818102867900_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3892\/ijmm.2016.2583","article-title":"Effects of IRF1 and IFN-\u03b2 interaction on the M1 polarization of macrophages and its antitumor function","volume":"38","author":"Xie","year":"2016","journal-title":"Int J Mol Med"},{"key":"2025032818102867900_bib16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41467-021-22033-2","article-title":"Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway","volume":"12","author":"Alicea-Torres","year":"2021","journal-title":"Nat Commun"},{"key":"2025032818102867900_bib17","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025032818102867900_bib18","doi-asserted-by":"crossref","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"2025032818102867900_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CMR.0000000000000352","article-title":"M1 and M2 macrophages\u2019 clinicopathological significance in cutaneous melanoma","volume":"27","author":"Falleni","year":"2017","journal-title":"Melanoma Res"},{"key":"2025032818102867900_bib20","first-page":"vdaa177","article-title":"Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases","volume":"3","author":"Fischer","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2025032818102867900_bib21","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1158\/2326-6066.CIR-21-0870","article-title":"Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition","volume":"10","author":"Alvarez-Breckenridge","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025032818102867900_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025032818102867900_bib23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"},{"key":"2025032818102867900_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025032818102867900_bib25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12498","article-title":"The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations","volume":"29","author":"Meeth","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025032818102867900_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41416-020-01090-2","article-title":"The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence","volume":"124","author":"Rabbie","year":"2021","journal-title":"Br J Cancer"},{"key":"2025032818102867900_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"2025032818102867900_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13046-023-02832-9","article-title":"Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming","volume":"42","author":"Zeng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"2025032818102867900_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cellimm.2013.07.008","article-title":"Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes","volume":"284","author":"Zhao","year":"2013","journal-title":"Cell Immunol"},{"key":"2025032818102867900_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jlb.62.3.349","article-title":"Expression and function of the early activation antigen CD69 in murine macrophages","volume":"62","author":"Marzio","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2025032818102867900_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025032818102867900_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"2025032818102867900_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-2215-7-19","article-title":"A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J Ovarian Res"},{"key":"2025032818102867900_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2025032818102867900_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"2025032818102867900_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"2025032818102867900_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-05-2856","article-title":"The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma","volume":"66","author":"Bevaart","year":"2006","journal-title":"Cancer Res"},{"key":"2025032818102867900_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"2025032818102867900_bib39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","article-title":"Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions","volume":"3","author":"DiLillo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2025032818102867900_bib40","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3390\/cancers15102752","article-title":"The role of TRAIL in apoptosis and immunosurveillance in cancer","volume":"15","author":"Pimentel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025032818102867900_bib41","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.7150\/jca.86735","article-title":"TNFSF10, an autophagy related gene, was a prognostic and immune infiltration marker in skin cutaneous melanoma","volume":"14","author":"Xue","year":"2023","journal-title":"J Cancer"},{"key":"2025032818102867900_bib42","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neo.2021.08.004","article-title":"Copy number alteration of the interferon gene cluster in cancer: individual patient data meta-analysis prospects to personalized immunotherapy","volume":"23","author":"Razaghi","year":"2021","journal-title":"Neoplasia"},{"key":"2025032818102867900_bib43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"2025032818102867900_bib44","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","article-title":"Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis","volume":"76","author":"Xia","year":"2016","journal-title":"Cancer Res"},{"key":"2025032818102867900_bib45","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/cancers15092432","article-title":"Novel mechanisms and future opportunities for the management of radiation necrosis in patients treated for brain metastases in the era of immunotherapy","volume":"15","author":"Vaios","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025032818102867900_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13014-020-01644-x","article-title":"Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases","volume":"15","author":"Kowalski","year":"2020","journal-title":"Radiat Oncol"},{"key":"2025032818102867900_bib47","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3348\/kjr.2020.0728","article-title":"Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: a systematic review and meta-analysis","volume":"22","author":"Kim","year":"2021","journal-title":"Korean J Radiol"},{"key":"2025032818102867900_bib48","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1002\/cncr.33196","article-title":"Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non\u2013small cell lung cancer and melanoma brain metastases","volume":"126","author":"Qian","year":"2020","journal-title":"Cancer"},{"key":"2025032818102867900_bib49","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"2025032818102867900_bib50","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0024\/3481011\/crc-24-0024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/2189\/3516216\/crc-24-0024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/2189\/3516216\/crc-24-0024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:30:33Z","timestamp":1743190233000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/8\/2189\/747291\/Tumoral-Interferon-Beta-Induces-an-Immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0024","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.26797538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688596","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688611","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688605","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628013","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797553.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628001","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797544","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797526","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628019","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797547.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797544.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797550","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797541.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797550.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688593","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797535.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797538.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688602","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688599","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797541","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797553","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688614","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797526.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797523","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797517.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628016","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797547","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688608","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27628004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797529.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797523.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26797520.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7412474.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7412474","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}